Show simple item record

dc.contributor.authorWoestenberg, Petra J
dc.contributor.authorKing, Audrey J
dc.contributor.authorvan Benthem, Birgit H B
dc.contributor.authorDonken, Robine
dc.contributor.authorLeussink, Suzan
dc.contributor.authorvan der Klis, Fiona R M
dc.contributor.authorde Melker, Hester E
dc.contributor.authorvan der Sande, Marianne A B
dc.contributor.authorHoebe, Christian J P A
dc.contributor.authorBogaards, Johannes A
dc.date.accessioned2018-03-22T12:54:58Z
dc.date.available2018-03-22T12:54:58Z
dc.date.issued2018-01-04
dc.identifier.citationBivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. 2018, 217 (2):213-222 J. Infect. Dis.en
dc.identifier.issn1537-6613
dc.identifier.pmid29140439
dc.identifier.doi10.1093/infdis/jix582
dc.identifier.urihttp://hdl.handle.net/10029/621696
dc.description.abstractObservational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population.
dc.language.isoenen
dc.rightsArchived with thanks to The Journal of infectious diseasesen
dc.titleBivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.en
dc.typeArticleen
dc.identifier.journalJ Infect Dis 2018; 217(2):213-22en
refterms.dateFOA2018-12-18T14:12:32Z
html.description.abstractObservational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population.


Files in this item

Thumbnail
Name:
jix582.pdf
Size:
201.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record